Published by Josh White on 26th October 2020
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.